Cargando…
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial
OBJECTIVE: To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX15/2503 in a randomized, single-dose, dose-escalation, double-blind, placebo-controlled study enrolling adult patients with MS. METHODS: Single IV doses of VX15/2503 or placebo were administered. T...
Autores principales: | LaGanke, Christopher, Samkoff, Lawrence, Edwards, Keith, Jung Henson, Lily, Repovic, Pavle, Lynch, Sharon, Stone, Lael, Mattson, David, Galluzzi, Aaron, Fisher, Terrence L., Reilly, Christine, Winter, Laurie A., Leonard, John E., Zauderer, Maurice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473956/ https://www.ncbi.nlm.nih.gov/pubmed/28642891 http://dx.doi.org/10.1212/NXI.0000000000000367 |
Ejemplares similares
-
Saturation monitoring of VX15/2503, a novel semaphorin 4D‐specific antibody, in clinical trials
por: Fisher, Terrence L., et al.
Publicado: (2015) -
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
por: Evans, Elizabeth E., et al.
Publicado: (2022) -
PB2503: MODULATION OF ERYTHROCYTE FUNCTION BY ENDOTHELIN-1
por: Teixeira-Alves, Lyzes Rosa, et al.
Publicado: (2023) -
Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D
por: Evans, Elizabeth E, et al.
Publicado: (2015) -
Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations
por: Evans, Elizabeth E, et al.
Publicado: (2015)